Recipharm expands Indian injectable dosage form capabilities through new partnership
Recipharm, the contract development and manufacturing organisation (CDMO), will enter a project together with long-term Indian partner Sobti family aimed at creating production capacity in India for a range of sterile dosage forms. The Sobti family’s newly created company Nichepharm Lifesciences Pvt Ltd (“Nichepharm”) will initially issue an 8% equity stake to Recipharm for an investment of 800 Million INR (approximately 110 million SEK). In addition, Recipharm will have the option to acquire an additional 16% share in Nichepharm during 2021. The new facility that will be established in